GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (AQSE:MYIG) » Definitions » Retained Earnings

Mydecine Innovations Group (AQSE:MYIG) Retained Earnings : £-91.07 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mydecine Innovations Group Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Mydecine Innovations Group's retained earnings for the quarter that ended in Jun. 2024 was £-91.07 Mil.

Mydecine Innovations Group's quarterly retained earnings increased from Dec. 2023 (£-91.34 Mil) to Mar. 2024 (£-90.78 Mil) but then declined from Mar. 2024 (£-90.78 Mil) to Jun. 2024 (£-91.07 Mil).

Mydecine Innovations Group's annual retained earnings declined from Dec. 2021 (£-73.39 Mil) to Dec. 2022 (£-81.08 Mil) and declined from Dec. 2022 (£-81.08 Mil) to Dec. 2023 (£-91.34 Mil).


Mydecine Innovations Group Retained Earnings Historical Data

The historical data trend for Mydecine Innovations Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Retained Earnings Chart

Mydecine Innovations Group Annual Data
Trend Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.01 -54.76 -73.39 -81.08 -91.34

Mydecine Innovations Group Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.82 -88.68 -91.34 -90.78 -91.07

Mydecine Innovations Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Mydecine Innovations Group  (AQSE:MYIG) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Mydecine Innovations Group Business Description

Traded in Other Exchanges
Address
1890 – 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group Headlines

No Headlines